Bristol-Myers Squibb advances heart and oncology pipeline, shares backed by steady dividends
28.06.2026 - 12:25:31 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 12:25.
Bristol-Myers Squibb (US1078421011) enters the final days of June with a mix of dividend support and pipeline updates as the shares trade on the NYSE under ticker BMY in US dollars. Consensus data point to a Hold stance and mid-60s dollar price targets from several analyst houses.
What recent data show
Recent coverage of Bristol-Myers Squibb highlights a quarterly dividend of 0.63 dollars per share, implying an annualized payout of 2.52 dollars and a yield around 4.4 percent on a mid-50s share price basis. According to MarketBeat, the next dividend is scheduled for payment in early August to shareholders of record as of early July.
Institutional investors continue to adjust positions in the company, with reports of a regional US bank lifting its stake in the first quarter by more than 70 percent to over 70,000 shares, valuing the position at roughly 4.3 million dollars at the time of the filing. This type of activity underpins the stock's role as a large-cap income and value name within the S&P 500 healthcare segment.
Analyst views and pipeline focus
Analyst commentary in late June presents a nuanced picture: one data aggregation notes an average rating of Hold and a consensus target price slightly above 61 dollars, suggesting modest upside from recent trading ranges. Another update cites Citi lifting its Bristol-Myers price target from 64 to 66 dollars while keeping a Neutral rating after revisiting the model following the first-quarter results.
On the pipeline side, Bristol-Myers has been linked to real-world data collection in Japan for mavacamten in hypertrophic cardiomyopathy, marketed as Camzyos in key regions, underlining management's focus on evidence generation for cardiovascular assets. The company also reported success earlier this year in a pivotal multiple myeloma trial with mezigdomide, a next-generation cereblon modulator seen as a successor to Pomalyst, with the phase III portion of the Successor-2 study meeting its primary progression-free survival endpoint.
More news and data on the Bristol-Myers Squibb shares
All current coverage, filings and price data on Bristol-Myers Squibb can be found in the dedicated topic section and on the company’s Investor Relations site.
The product behind the stock
Bristol-Myers Squibb generates a significant portion of its revenue from oncology and cardiovascular therapies, with Camzyos (mavacamten) standing out as a targeted treatment for obstructive hypertrophic cardiomyopathy in adults with preserved ejection fraction. The capsule is prescribed by cardiologists and supplied via specialty pharmacies, adding a focused cardiovascular revenue stream alongside broader oncology and immunology portfolios.
Where the stock trades today
The Bristol-Myers Squibb shares (US1078421011) last closed on the NYSE at 57.45 dollars on 2026-06-26, 15:59 Eastern, implying a market capitalization in the tens of billions of dollars for the S&P 500 constituent.
Key data on the Bristol-Myers Squibb shares
- Company: Bristol-Myers Squibb Company
- ISIN: US1078421011
- WKN: 850403
- Ticker: BMY
- Trading venue: NYSE
- Price (as of 2026-06-26, 15:59): 57.45 USD
- Market cap: approximately 119 billion USD (as of 2026-06-26)
- Sector / industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell any security. All data are based on publicly available sources considered reliable at the time of publication but may change without notice.
